Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Daiichi Sankyo Loses One, Gains One In Oncology

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo has unveiled disappointing results for one pipeline molecule that has now been suspended for lung cancer, but has gained another for breast cancer as it continues to develop its oncology portfolio.


Related Content

Daiichi Sankyo Lays Out Priorities As It Pursues Oncology Ambitions
Daiichi Presses On With Lead Pexidartinib Trial Despite Liver Toxicity


Related Companies

Related Deals